Imaging the role of amyloid in PD dementia and dementia with Lewy bodies (Q38228098)

31 August 2017

Imaging the role of amyloid in PD dementia and dementia with Lewy bodies (English)

1 reference

31 August 2017

0 references

Stephen N Gomperts

1

1 reference

31 August 2017

1 August 2014

1 reference

Current Neurology and Neuroscience Reports

31 August 2017

1 reference

31 August 2017

14

1 reference

31 August 2017

8

1 reference

31 August 2017

472

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-014-0472-6

31 August 2017

0 references

cites work

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Aβ amyloid, cognition, and APOE genotype in healthy older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Meta-analysis of amyloid-cognition relations in cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Relation between clinical characteristics of Parkinson's disease and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Relationship of motor symptoms to intellectual deficits in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cholinergic dysfunction in diseases with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The many faces of alpha-synuclein mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathology of dementia in a large cohort of patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathologic substrates of Parkinson disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The neurobiological basis of cognitive impairment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathology of Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

A clinico-pathological study of subtypes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Dementia with Lewy bodies: neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging of Lewy body-associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Brain amyloid and cognition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[11C]PIB binding in Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Multimodality imaging characteristics of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Impact of molecular imaging on the diagnostic process in a memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Changes in motor subtype and risk for incident dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF Aβ42 predicts early-onset dementia in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Interaction between pathogenic proteins in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Biomarkers in dementia with Lewy bodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

What can biomarkers tell us about cognition in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Tau pathology and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Predictors of survival in dementia with lewy bodies and Parkinson dementia

21 January 2018

1 reference

12 December 2020

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

1 reference

12 December 2020

Dementia with Lewy bodies

1 reference

12 December 2020

Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.

1 reference

12 December 2020

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

1 reference

12 December 2020

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

12 December 2020

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease

1 reference

12 December 2020

Cortical Lewy body pathology in the diagnosis of dementia.

1 reference

12 December 2020

PET imaging of neuropathology in tauopathies: progressive supranuclear palsy

1 reference

12 December 2020

Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes

1 reference

12 December 2020

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers

1 reference

12 December 2020

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

1 reference

12 December 2020

A Population-Based Investigation of Parkinson's Disease With and Without Dementia

1 reference

12 December 2020

A highly selective and specific PET tracer for imaging of tau pathologies

1 reference

12 December 2020

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

1 reference

12 December 2020

10.1007/S11910-014-0472-6

Identifiers

DOI

1 reference

PubMed ID

25011528

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

25011528